LCM
IMPL

Laurion Capital Management’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Laurion Capital Management’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-124,800
Closed -$158K – 723
2023
Q2 		$158K Hold
124,800
– – ﹤0.01% 497
2023
Q1 		$175K Hold
124,800
– – ﹤0.01% 390
2022
Q4 		$468K Hold
124,800
– – ﹤0.01% 359
2022
Q3 		$608K Hold
124,800
– – ﹤0.01% 390
2022
Q2 		$1.16M Buy
+124,800
New +$912K 0.02% 267

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Laurion Capital Management's IMPL Position: Q3 2023 in Review

Laurion Capital Management sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q3 2023, closing a stake of 124,800 shares — an estimated $158K sold.

Laurion Capital Management first reported a position in IMPL in Q2 2022 and held it in 5 quarters. The position peaked at $1.16M in Q2 2022. 32 funds tracked by Wall St. Rank hold IMPL as of Q3 2023.

  • Laurion Capital Management reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Laurion Capital Management sold 124,800 Impel Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $158K.
  • Laurion Capital Management first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • Laurion Capital Management's Impel Pharmaceuticals Inc. Common Stock position peaked at $1.16M in Q2 2022.
  • 32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.